Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01928303 · ClinicalTrials.gov registry record
Predicting Oxycodone Dose From Oral Fluid Drug Levels
A clinical trial, sponsored by Weill Medical College of Cornell University.
- Completed
- Registry status
- 55
- Enrollment target
NCT01928303: Completed study, sponsored by Weill Medical College of Cornell University.
NCT01928303 is a clinical trial that has completed, run by Weill Medical College of Cornell University. The registered enrollment target is 55 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01928303 has completed, sponsored by Weill Medical College of Cornell University.
- COMPLETED
- Registry status
- 55 participants
- Enrollment target
Study Summary
This study will develop and test an algorithm that will estimate drug dosage from drug levels measured in oral fluid (saliva). Traditionally, urine has been used as the principle medium to monitor drug compliance in patients receiving opioids for chronic pain as well as those being treated for substance abuse. Recently, the use of saliva as an alternative to urine drug testing has been gaining in popularity. Oral fluid has several advantages over urine as a medium for drug screening. In this study, oral fluid, urine and blood specimens will be collected from volunteer patient donors with chronic pain taking opioid medications. Samples from the anonymous donor will be analyzed for opiate class drugs, using New York State Department of Health approved and validated laboratory methods. Analytical results and other information collected will assist in evaluating the use of oral fluid as a specimen to detect opiate drug levels. The measurement of drug concentrations in blood and oral fluid simultaneously will allow for the determination of the amount of oral fluid that will be needed for successful drug testing. It is proposed that by measuring oral fluid drug levels an estimate of the amount of drug taken will be possible.
Primary Outcome
The primary goal of the study is to develop and test an algorithm that will estimate drug dosage from measured oral fluid drug levels.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 55 participants |
| Start Date | 2013-03 |
| Est. Completion | 2014-08 |
What the finished NCT01928303 record still lists
NCT01928303 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 55 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT01928303 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01928303 about?
NCT01928303 is a clinical study titled "Predicting Oxycodone Dose From Oral Fluid Drug Levels". This study will develop and test an algorithm that will estimate drug dosage from drug levels measured in oral fluid (saliva). Traditionally, urine has been used as the principle medium to monitor drug compliance in patients receiving opioids for chronic pain as well as those being treated for subst...
What is the current status of trial NCT01928303?
This trial is currently completed. The enrollment target is 55 participants. The study started on 2013-03. Estimated completion is 2014-08.
Who is sponsoring clinical trial NCT01928303?
This trial is sponsored by Weill Medical College of Cornell University, which has 701 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01638676 · 55 participants · Phase 1
A Phase I/II Trial of Vemurafenib and Metformin to Melanoma Patients
- NCT01906385 · 55 participants · Phase 1
Maximum Tolerated Dose, Safety, and Efficacy of Rhenium Nanoliposomes in Recurrent Glioma (ReSPECT)
- NCT03007030 · 55 participants · Phase 2
Brentuximab Vedotin in Treating Patients With CD30+ Malignant Mesothelioma That Cannot Be Removed by Surgery
- NCT03152058 · 55 participants · Phase 2
IMPACT Study: IMProve Pregnancy in APS With Certolizumab Therapy
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia